ReviewAmerican journal of neurodegenerative disease2025
Advances in nanotechnology for targeted drug delivery in neurodegenerative diseases.
Review in American journal of neurodegenerative disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Quercetin-Based Nanotherapeutics for Targeted Drug Delivery in Alzheimer's Disease: Comparative Insights into Molecular Mechanisms, Blood-Brain Barrier Targeting and Therapeutic Perspectives.Molecular neurobiology · 2026Review
- Emerging therapeutic strategies in multiple sclerosis: a focus on innovative and targeted approaches.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Intranasal delivery route for neurodegenerative diseases: recent insights and future directions.Drug delivery and translational research · 2026Review
- Quo Vadis translational neuroscience?Translational neuroscience · 2026Review
- A comparative study of artifact reduction techniques in metal-implanted CT scans.International journal of physiology, pathophysiology and pharmacology · 2026Review
- Advancing cardiac tumor diagnosis: evaluatingAmerican journal of cardiovascular disease · 2026Review
- Diagnostic accuracy of ultrasound compared to magnetic resonance imaging for rotator cuff tears: a systematic review.International journal of burns and trauma · 2026Article
- Targeted Nanoparticles for Drug Delivery Across the Blood-Brain Barrier in Early and Late Stages of Alzheimer's Disease: A Review.Molecular neurobiology · 2025Review
- Editorial: New approaches to overcome the blood-brain barrier for the treatment of CNS disorders.Frontiers in cellular neuroscience · 2025Article
- The dual role of SGLT2 inhibitors: glycemic control and cardioprotection in anthracycline-treated cancer patients.International journal of physiology, pathophysiology and pharmacology · 2025Review
- Comparative risk of osteoporotic fractures with direct oral anticoagulants versus vitamin K antagonists in atrial fibrillation patients: a systematic review.International journal of burns and trauma · 2025Review
- Diagnostic challenges in cardiac amyloidosis: a case report of negative initial endomyocardial biopsy.International journal of physiology, pathophysiology and pharmacology · 2025Article
- Evaluating the efficacy of precise platelet-rich plasma injection in grade II meniscus tears.International journal of burns and trauma · 2025Article
- The zero calcium score paradox and multivessel obstructive disease: a case report of a patient with zero CAC score.American journal of cardiovascular disease · 2025Article
- Tuberculous spondylodiscitis with ureteral involvement: a rare case report.American journal of clinical and experimental urology · 2025Article
- Using ultrasonographic features in pediatric Crohn's disease activity index severity.International journal of physiology, pathophysiology and pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurodegenerative diseases, including Alzheimer's, Parkinson's, and multiple sclerosis, are a growing healthcare challenge due to their impact on quality of life and the difficulty in treating them. These disorders are associated with brain lesions and barriers, such as the blood-brain barrier (BBB), that impede effective treatment. Nanotechnology, especially functionalized nanoparticles (NPs), is emerging as a promising tool for overcoming these barriers. Nanoparticles, such as liposomes, polymeric micelles, and gold nanoparticles (AuNPs), show potential for targeted drug and gene delivery to the brain, enhancing bioavailability, circulation time, and treatment efficacy. Nanocarrier-based systems have demonstrated success in protecting nucleic acids from degradation, improving BBB penetration, and delivering genetic material to target specific brain areas. Exosomes and artificial vesicles also hold promise for their size and biocompatibility. Gold nanoparticles are gaining attention for their neuroprotective and anti-inflammatory properties, particularly in treating Alzheimer's, Parkinson's, and stroke. These systems can modify gene expression and address the underlying mechanisms of these diseases. In addition to drug delivery, noninvasive strategies like intranasal administration are being explored to enhance patient adherence. However, challenges remain, including regulatory hurdles and the need for further research to optimize these technologies. As research advances, the synergy between materials science, bioengineering, and medicine will pave the way for more effective treatments for neurodegenerative diseases. The aim of this study is to explore the potential of functionalized NPs in overcoming the BBB and improving targeted drug delivery for the treatment of neurodegenerative diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.